Drug profile · INN
radamts13
ADZYNMA
radamts13 (ADZYNMA) is a a disintegrin and metalloproteinase with thrombospondin motifs 13 exogenous protein. Associated with Takeda.
EMA: approved Blood and blood forming organs (B01) B01AD13
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — radamts13
- Class
- Blood and blood forming organs (B01)
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.89
Quick answer
radamts13 (ADZYNMA) is a a disintegrin and metalloproteinase with thrombospondin motifs 13 exogenous protein. Associated with Takeda.
Key facts
INN radamts13
Brand ADZYNMA
Mechanism A disintegrin and metalloproteinase with thrombospondin motifs 13 exogenous protein
Target A disintegrin and metalloproteinase with thrombospondin motifs 13
Therapeutic class Blood and blood forming organs (B01)
ATC code B01AD13
Originator Takeda
Mechanism of action
A disintegrin and metalloproteinase with thrombospondin motifs 13 exogenous protein
Primary target: A disintegrin and metalloproteinase with thrombospondin motifs 13
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is radamts13?
radamts13 (ADZYNMA) is a a disintegrin and metalloproteinase with thrombospondin motifs 13 exogenous protein. Associated with Takeda.
What is the brand name for radamts13?
ADZYNMA is a marketed brand name for radamts13. Check FDA Drugs@FDA for the current US label holder and prescribing information.